Macrolide Pharmaceuticals

Macrolide Pharmaceuticals focuses on the discovery and development of novel macrolide antibiotics for the treatment of life-threatening bacterial infections caused by drug resistant pathogens. Using novel technology, Macrolide Pharmaceuticals can synthesize a broad range of macrolides and initial compounds that show promising anti-bacterial activity.

Macrolide Pharmaceuticals’ strategy is based on unique chemistry developed by Prof. Andrew Myers of Harvard University. Waypoint co-led the 2015 $22 million Series A financing of Macrolide, joined by the Novartis Venture Fund, Roche Ventures, and SROne (GSK’s venture fund). The financing followed a worldwide license agreement between Harvard’s Office of Technology Development and Macrolide, providing exclusive rights to the technology.